CAR-T for Patients with Renal Impairment
A Pilot Safety and Feasibility Study of Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 12 patients (estimated)
- Sponsors
- Washington University School of Medicine
- Collaborators
- American Cancer Society
- Tags
- CAR T Cell, B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1998
- NCT Identifier
- NCT06623630
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.